Use of bluetongue virus proteins as vaccine components
CA 2075945 A1 · Owner: Oxford Virology Plc · Inventors: Roy, Polly; French, Timothy J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A protective effect against bluetongue infection in susceptible mammals which is obtained by inoculating said mammals with a polypeptide comprising at least an antigenic portion of bluetongue virus structural protein VP2 in antigenic form produced by transforming a host with a recombinant expression vector having a DNA segment coding for said polypeptide.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 6, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 6, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 6, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.